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Introduction: Predicting severity of pancreatitis is an important goal. Clinicians are still searching for novel and
simple biomarkers that can better predict persistent organ failure (OF). Lipoproteins, especially high-density lipoprotein
(HDL), and apolipoprotein A-I (APO A-I), have been shown to have anti-inflammation effects in various clinical settings.
Severe acute pancreatitis (SAP) is associated with hypo-lipoproteinemia. We studied whether the concentrations of HDL
and APO A-I can predict persistent OF in patients with predicted SAP admitted to the ICU.
Methods: In 66 patients with predicted SAP, we prospectively evaluated the relationship between lipid levels,
inflammatory cytokines and clinical outcomes, including persistent OF and hospital mortality. Blood samples were
obtained within 24 hours of admission to the ICU.
Results: HDL and APO A-I levels were inversely correlated with various disease severity scores. Patients with persistent
OF had lower levels of HDL and APO A-I, while those with transient OF had lower levels of interleukin-6, tumor necrosis
factor-α and lower rates of hospital mortality. Meanwhile, hospital non-survivors had lower concentrations of HDL, and
APO A-I compared to the survivors. By using the area under the receiver operating characteristic (AUROC) curve, both
HDL and APO A-I demonstrated an excellent discriminative power for predicting persistent OF among all patients
(AUROC 0.912 and 0.898 respectively) and among those with OF (AUROC 0.904 and 0.895 respectively). Pair-wise
comparison of AUROC showed that both HDL and APO A-I had better discriminative power than C-reactive protein to
predict persistent OF.
Conclusions: Serum levels of HDL and APO A-I at admission to the ICU are inversely correlated with disease severity in
patients with predicted SAP and can predict persistent OF in this clinical setting.Introduction
Acute pancreatitis represents an acute inflammatory dis-
order with variable severity ranging from mild, self-limited
disease to a severe inflammatory cascade associated with
multiple-organ failure. Despite the improvements in crit-
ical care, severe acute pancreatitis (SAP) is still associated
with a high mortality rate [1]. Although the incidence of
organ failure in the early phase (within the first week) var-
ies among different studies [2-6], persistent organ failure
(OF) has been shown to be the major determinant of* Correspondence: mhtsai@cgmh.org.tw
3Division of Digestive Therapeutic Endoscopy, Chang Gung Memorial
Hospital, 199, Tung-Hwa North Road, Taipei, Taiwan
9Chang Gung University, College of Medicine, 259, Wen-Hwa 1st Road,
Kwei-Shan, Tao-Yuan, Taiwan
Full list of author information is available at the end of the article
© 2015 Peng et al.; licensee BioMed Cen
Commons Attribution License (http://cre
reproduction in any medium, provided t
Dedication waiver (http://creativecommo
unless otherwise stated.tral. T
ativec
he or
ns.orclinical outcomes [6,7]. These observations have led to
modified definitions of SAP, which recognize the import-
ance of persistent OF and introduce a new sub-
classification of moderately severe pancreatitis based on
the presence of transient OF [8,9].
It is important to stratify the severity of acute pancrea-
titis. First, early identification of patients with potential
SAP may facilitate timely referral to specialists. Second,
for specialists, severity-stratification of those patients
makes triage and comparison between different studies
possible. However, when organ failure is present in the
early phase, it may be difficult to determine the final de-
gree of severity because it is unknown whether the pa-
tient will prove to have persistent or transient OF.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cholesterol and lipoproteins decrease in the early stages
of critical illness [10-12]. Indeed, the pattern of early
rapid decline is found primarily in the high-density lipo-
protein (HDL) [12]. Moreover, the protein composition
of HDL is markedly altered as well, with the apolipopro-
tein A1 (APO A-I) depleted [12].
Apo A-I is the major protein component of HDL.
APO A-I plays an essential role in cholesterol homeosta-
sis by transporting excessive cholesterol from extra-
hepatic tissues to the liver. Aside from this biological
function, recently, more emphasis has been placed upon
its anti-inflammatory effects. Apo A-I can attenuate
lipopolysaccharide-induced cytokine secretion in a mode
of protein-endotoxin interaction, even without its
physiological lipid complement [13,14]. Furthermore, el-
evated cytokines can downregulate hepatic synthesis of
HDL and APO A-I [15].
Although there have been studies of lipoprotein profile
in acute pancreatitis [16-18], there has been no report
on the specific role of lipoprotein in predicting severity
using the most updated definition. The results of previ-
ous studies raise the possibility that the levels of lipopro-
tein may play a role in assessing disease severity [17,18].
However, these studies had several limitations, including
retrospective design [17], and inconsistent definitions of
severity ranging from severe pancreatitis based on the
Atlanta criteria to mortality [17,18]. None of these stud-
ies evaluated persistent OF, which has become recog-
nized as the most clinically relevant indicator of disease
severity. Furthermore, these studies have mainly focused
on the analysis of total cholesterol, triglycerides, LDL or
HDL cholesterol. APO A-I levels have rarely been re-
ported, even though APO A-I represents the major pro-
tein component of HDL, modulating inflammation.
We hypothesized that low levels of lipoprotein are as-
sociated with a more pronounced inflammatory state in
patients with predicted SAP and may serve as a marker
to discriminate persistent OF from transient OF upon
admission to ICU. Therefore, we conducted this pro-
spective observational investigation to study whether
low concentrations of APO A-I and HDL are associated
with persistent OF and hospital mortality. Other poten-
tial indicators of inflammation such as C-reactive pro-
tein (CRP), TNF-α and IL-6 were also measured.
Material and methods
Patient information, data collection and definitions
This study was conducted with the approval of the insti-
tutional review board of Chang Gung Memorial Hos-
pital, Taiwan and in accordance with the Declaration of
Helsinki of the World Medical Association. Formal con-
sent was obtained from the patient or the next of kin.
The study was performed in the ICU of two university-affiliated hospitals between February 2008 and September
2011. This study enrolled 66 patients with predicted SAP
requiring intensive monitoring and/or treatment. Pre-
dicted SAP was defined by acute physiology, age, and
chronic health evaluation (APACHE II) score ≥8 at admis-
sion [19]. All patients included in this study were admitted
to hospital within 72 hours of onset of symptoms.
The diagnosis of acute pancreatitis was made based on
two or more of the following: typical abdominal pain;
serum amylase and/or lipase levels at least three times
the upper limit of normal; and characteristic findings of
acute pancreatitis on a contrast-enhanced computed
tomography (CT) scan, or abdominal ultrasonography.
Abdominal ultrasonography was performed for each
case at presentation. Enhanced CT was performed when
the disease was evaluated as predicted SAP. CT-guided
aspiration was performed and bacterial cultures were ob-
tained when infected necrosis was suspected.
Organ failure was defined as a score of ≥2 in one or
more of the three (respiratory, renal, and cardiovascular)
organ systems described in the modified Marshall score
during the first week [20,21]. This definition is in ac-
cordance with the most updated revised Atlanta classifi-
cation [8,9]. OF was defined as transient for duration
<48 hours or persistent if >48 hours. Meanwhile, disease
severity also was assessed by sequential organ failure as-
sessment (SOFA) [22].
Patients with a history of prior acute pancreatitis or
drug history of lipid-lowering agents, and patients those
receiving total parenteral nutrition at the time of blood
sampling were excluded from this study. All ICU admis-
sions were followed until discharge from the hospital or
hospital mortality.
Laboratory investigations
Blood cultures and appropriate cultures from the infec-
tion focus were obtained. Hematological and biochem-
ical data including serum lipoprotein were also collected
systemically within 24 hours of admission to ICU, with a
median of 3 days (IQR 2 to 4 days) after the start of
symptoms and a median of 2 days (IQR 1 to 3 days)
after admission to hospital. For the scoring systems, the
most abnormal value for each organ system on the day
of blood sampling was recorded.
A fasting blood sample was obtained in the morning.
The blood samples were allowed to clot and were spun
immediately in a refrigerated centrifuge. The serum was
obtained and frozen at −80°C. Total cholesterol (TC)
and triglyceride (TG) were measured enzymatically using
kits (Wako Pure Chemical, Osaka, Japan). The concen-
trations of HDL and LDL were directly measured using
a homogenous assay (Daiichi Pure Chemical, Ibaraki,
Japan). APO A-I was measured by means of immunotur-
bidimetry with the TurbiTime system (Dade Behring
Peng et al. Critical Care  (2015) 19:88 Page 3 of 9Inc, Newark, DE, USA). The concentrations of TNF-α
and IL-6 were measured by an enzyme-linked immuno-
sorbent assay (R & D Systems, Minneapolis, MN, USA).
CRP was measured by a latex-enhanced immunoturbidi-
metric method (Daiichi Pure Chemical).
Statistical analysis
Descriptive statistics are expressed as mean ± SD. All
variables were tested for normal distribution using the
Kolmogorov-Smirnov test. The Student t-test was used
to compare the means of continuous variables and theTable 1 Patients’ demographic data and clinical characteristic
Hospital survivors
(n = 53)
Age, years 60 (45 to 76.5)
Gender, M/F, number 29/24
BMI, kg/m2 25.9 ± 4.0
Body weight, kg 67.6 ± 12.1
Etiology, alcohol/biliary/ERCP/others 19/31/0/3
Leukocytes, ×109/l 11.8 ± 5.7
Hemoglobin, g/dl 10.4 ± 2.1
Platelets, ×109/l 157.5 (88.3 to 241)
BUN, mg/dl 17.5 (10.8 to 26.5)
Serum creatinine, mg/dl 0.9 (0.7 to 1.9)
Bilirubin, mg/dl 1.5 (0.9 to 3)
INR 1.2 (1.1 to 1.4)
Ranson score 5 (4 to 6)
APACHE II score 15 (11 to 20.8)
SOFA score 5 (3 to 8)
Modified Marshall score 3 (2 to 5.5)
Organ failure 42 (79.2%)
Number of organ failures 1 (1 to 2)
Respiratory failure 38 (71.7%)
Renal failure 21 (39.6%)
Cardiovascular failure 13 (24.5%)
Infected necrosis, n 10 (18.9%)
Persistent organ failure, n 22 (41.5%)
Cholesterol, mg/dl 122 (92 to 152)
Triglyceride, mg/dl 140 (107 to 239)
HDL, mg/dl 17 (11 to 31)
LDL, mg/dl 61 (40 to 79)
APO A-I, mg/dl 67 (50 to 83)
IL-6, pg/ml 73 (39.7 to 177.8)
TNF-α, pg/ml 6.2 (2.9 to 13.5)
CRP, mg/l 182.6 ± 115.6
Results are presented as mean ± SD, or median (IQR) unless otherwise stated. M, ma
cholangiopancreagraphy; BUN, blood urea nitrogen; INR, international normalized r
sequential organ failure assessment; HDL, high-density lipoprotein; LDL, low-densitynormality of data distribution. Otherwise, the Mann-
Whitney U-test was used. Categorical data were tested
using the chi-square (χ2) test. The Kruskall-Wallis test
followed by Dunn’s post hoc test was used for multiple
comparison. Correlation between the lipid levels, cyto-
kines and the disease severity scores was analyzed with
the Spearman rank method. Discrimination was tested
using the area under a receiver operating characteristic
(ROC) curve (AUROC) to assess the ability of HDL
cholesterol and APO A-I to predict persistent OF. ROC
analysis was also performed to calculate the cutoffs
Hospital non-survivors P-value
(n = 13)
59 (45 to 84) 0.640
9/4 0.532
25.2 ± 3.7 0.597
69.2 ± 11.8 0.671
6/6/1/0 0.145
14.6 ± 0.9 0.301
10.3 ± 2.6 0.893
62 (25 to 216) 0.043
44 (14.5 to 91.5) 0.009
3.1 (1.8 to 5.4) 0.003
8 (2.7 to 22. 5) <0.001
1.5 (1.2 to 1.8) 0.007
6 (6 to 8.5) 0.001
28 (16.5 to 34.8) 0.002
13 (6.5 to 15.8) 0.001
9.5 (7 to 10.8) <0.001
13 (100%) 0.104






98 (81 to 139) 0.256
180 (102 to 362) 0.723
6 (4 to 13) <0.001
43 (30 to 91) 0.297
40 (23 to 46) <0.001
388 (125 to 831.5) 0.015
25 (20 to 42) 0.011
151.6 ± 77.4 0.382
le; F, female; BMI, body mass index; ERCP, endoscopic retrograde
atio; APACHE, acute physiology, age, and chronic health evaluation; SOFA,
lipoprotein; APO, A-I apolipoprotein A-I; CRP, C-reactive protein.
Figure 1 Association among apolipoprotein A-I (APO A-1),
high-density lipoprotein (HDL) and organ failure. The levels of
apolipoprotein A-I and HDL decrease progressively and significantly
with the number of organ failures. *P <0.05 compared to the group
with no organ system failure; **P <0.001 compared to the group
with no organ system failure (Kruskall-Wallis test followed by Dunn’s
post hoc test). Results are expressed as median, with error bars
representing the IQR.
Table 2 Correlation between serum lipid, disease severity scores, and serum inflammatory cytokines
Statistics Ranson score APACHE II score SOFA score Modified Marshall score TNF-α IL-6
Cholesterol R −0.198 −0.321 −0.367 −0.349 −0.335 −0.196
P 0.115 0.010 0.003 0.004 0.025 0.192
HDL R −0.376 −0.483 −0.613 −0.669 −0.450 −0.540
P 0.002 <0.001 <0.001 <0.001 0.001 <0.001
LDL R −0.165 −0.371 −0.335 −0.423 −0.285 −0.356
P 0.196 0.003 0.008 0.001 0.057 0.018
Triglyceride R 0.130 0.071 0.094 0.246 −0.012 0.185
P 0.301 0.579 0.463 0.048 0.937 0.219
APO A-I R −0.378 −0.467 −0.569 −0.597 −0.467 −0.471
P 0.002 <0.001 <0.001 <0.001 0.001 0.001
HDL, high-density lipoprotein; LDL, low-density lipoprotein; APO A-I, apolipoprotein A-I; APACHE, acute physiology and chronic health evaluation; SOFA, sequential
organ failure assessment.
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positive and negative predictive values (PPV and NPV).
The best Youden index (sensitivity + specificity-1) [23]
was also used to determine the best cutoff point of HDL
and APO A-I to predict persistent OF. All statistical
tests were two-tailed, and the significance level was set
at P ≤0.05. Data were analyzed using SPSS 18.0 for
Windows (SPSS Inc., Chicago, IL, USA) except for com-
parisons of ROC curve. The comparisons between ROC
curves were calculated with the MedCalc software (Med-




During the study period, 69 consecutive patients with
predicted SAP were admitted to ICU: 3 patients were
excluded because of prior history of acute pancreatitis,
and 66 patients were enrolled in this investigation.
Table 1 lists the patients’ demographic data and clinical
characteristics. Overall, the in-hospital mortality for the
entire group was 19.7%. Compared to hospital survivors,
the hospital non-survivors had higher disease severity as
evidenced by higher Ranson, APACHE II, SOFA, and
modified Marshall scores.
Lipid profile and mortality
The levels of HDL, and APO-A-I were significantly
higher in those who survived (Table 1), while the levels
of TNF-α and IL-6 were higher in those who died. Al-
though weak, HDL and APO A-I were inversely corre-
lated with Ranson, APACHE II, SOFA and modified
Marshall scores (Table 2). Among these, HDL had the
strongest negative correlation with the modified Marshall
score. Inflammatory cytokines were also negatively corre-
lated with HDL, and APO A-I. Of these, HDL had the
strongest inverse relationship with serum IL-6 levels. The
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sively and significantly with the number of organ failures
as defined by the modified Marshall score (Figure 1). The
discriminating power of APO A-I and HDL to predict 28-
day mortality was tested using the AUROC. The AUROC
for APO A-I and HDL to predict 28-day mortality was
0.869 ± 0.047 (mean ± standard error of the mean (SEM)),
95% CI 0.764 to 0.940, and 0.791 ± 0.059, 95% CI 0.673 to
0.881, respectively.
Lipid profile and organ failure
Table 3 lists the demographic data, clinical characteris-
tics and lipid profiles in patient subgroups stratified byTable 3 Patients’ demographic data and clinical characteristic
Organ failure
(n = 55)
Age, years 59 (45 to 76)
Gender, M/F, n 34/21
BMI, kg/m2 25.7 ± 3.8
Body weight, kg 68.3 ± 12.2
Etiology, alcohol/biliary/ERCP/others 21/30/1/3
Leukocytes, ×109/l 13.1 ± 6.6
Hemoglobin, g/dl 10.4 ± 2.3
Platelets, ×109/l 138 (72 to 229)
BUN, mg/dl 23 (12.5 to 41.5)
Serum Creatinine, mg/dl 1.5 (0.9 to 3.2)
Bilirubin, mg/dl 1.6 (1.1 to 5.4)
INR 1.2 (1.1 to 1.5)
Ransons score 5.5 (4 to 7)
APACHE II score 18 (11 to 25.5)
SOFA score 6 (4.3 to 9.8)
Modified Marshall score 5 (3 to 7.25)
Infected necrosis, n 18 (32.7%)
Cholesterol, mg/dl 117 (83 to 142)
Triglyceride, mg/dl 148 (105 to 285)
HDL, mg/dl 15 (6 to 22)
LDL, mg/dl 56 (37 to 75)
APO A-I, mg/dl 54 (41 to 74)
IL-6, pg/ml 129 (54 to 251.5)
TNF-α, pg/ml 10.8 (4.7 to 23)
CRP, mg/l 190.6 ± 108.9
Hospital mortality 13 (23.6%)
ICU mortality 9 (16.4%)
28-day mortality 11 (20%)
ICU stay, days 8 (5 to 14.5)
Results are presented as mean ± SD, or median (IQR) unless otherwise stated. M, ma
cholangiopancreagraphy; BUN, blood urea nitrogen; INR, international normalized r
organ failure assessment; HDL, high-density lipoprotein; LDL, low-density lipoproteithe presence of OF. The levels of total cholesterol, HDL,
LDL and APO A-I were significantly lower in patients
with OF, while the levels of TNF-α, IL-6 and CRP were
lower in those without OF. When persistency of organ
failure was not taken into account, there was no differ-
ence in mortality rates between patient with OF and
those without OF (Table 3).
HDL and APO A-I as markers to predict persistent organ
failure
To further demonstrate the association among lipid pro-
file, persistent OF and mortality, those patients with OF
were sub-grouped into transient OF and persistent OF.s stratified by early organ failure
No organ failure P-value
(n = 11)
69 (45 to 92) 0.429
4/7 0.182
26.2 ± 4.4 0.748
65.7 ± 10.9 0.545
4/7/0/0 0.815
9.1 ± 4.6 0.058
10.3 ± 1.5 0.936
139.5 (58.5 to 247.3) 0.935
12 (7 to 22) 0.023
0.7 (0.6 to 0.9) <0.001
1.5 (1 to 4) 0.642
1.05 (1 to 1.13) 0.002
4 (3 to 4) 0.001
14 (10 to 15) 0.028
3 (2 to 5) 0.005
1 (0 to 1) <0.001
0 (0%) 0.028
151 (109 to 172) 0.046
132 (92 to 167) 0.242
24 (19 to 33) 0.010
82 (65 to 100) 0.005
78 (55 to 96) 0.020
29 (10.4 to 101.5) 0.005
2.9 (1.1 to 3.7) 0.001




5 (5 to 11) 0.510
le; F, female; BMI, body mass index; ERCP, endoscopic retrograde
atio; APACHE, acute physiology and chronic health evaluation; SOFA, sequential
n; APO A-I, apolipoprotein A-I; CRP C-reactive protein.
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in patient subgroups stratified by persistency of OF. The
levels of total cholesterol, HDL, LDL and APO A-I were
significantly lower in patients with persistent OF, while
the levels of TNF-α, and IL-6 were higher in those with
persistent OF. The mortality rates were significantly
higher in patients with persistent OF, while ICU stay was
shorter in patients with transient OF. The discriminatingTable 4 Patients’ demographic data and clinical characteristic
Organ failure (transie
(n = 20)
Age, years 70.5 (46.5 to 80.3)
Gender, M/F, n 10/10
BMI, kg/m2 26.5 ± 4.3
Body weight, kg 66.4 ± 12.7
Etiology, alcohol/biliary/ERCP/others 4/15/0/1
Leukocytes, ×109/l 12.9 ± 5.6
Hemoglobin, g/dl 10.5 ± 2.6
Platelets, ×109/l 157.5 (104.5 to 240)
BUN, mg/dl 16.5 (7.5 to 26)
Serum Creatinine, mg/dl 0.9 (0.8 to 1.3)
Bilirubin, mg/dl 1.5 (0.8 to 1.9)
INR 1.2 (1.1 to 1.4)
Ranson score 5 (4 to 5.5)
APACHE II score 12 (10 to 17.8)
SOFA score 4.5 (2 to 6)
Modified Marshall score 3 (2 to 3)
Number of organ failures 1 (1 to 1.8)
Respiratory failure 17 (85%)
Renal failure 6 (30%)
Cardiovascular failure 3 (15%)
Infected necrosis 0 (0%)
Cholesterol, mg/dl 131.5 (117 to 170)
Triglyceride, mg/dl 144 (116 to 242)
HDL, mg/dl 30 (17 to 36)
LDL, mg/dl 66 (56 to 74)
APO A-I, mg/dl 81 (69 to 100)
IL-6, pg/ml 63.5 (43 to 136.5)
TNF-α pg/ml 6.3 (2.9 to 15)
CRP, mg/l 195.0 ± 91.4
Hospital mortality 0 (0%)
ICU mortality 0 (0%)
28-day mortality 0 (0%)
ICU stay, days 5 (3 to 9)
Results are presented as mean ± SD, or median (IQR) unless otherwise stated. M ma
cholangiopancreagraphy; BUN blood urea nitrogen; INR international normalized ra
organ failure assessment; HDL high-density lipoprotein; LDL low-density lipoproteinpower of APO A-I and HDL to predict persistent OF
was also tested using AUROC. When all patients with
predicted SAP were analyzed, the AUROC for APO A-I
and HDL to predict persistent OF was 0.898 ± 0.043
(mean ± SEM), 95% CI 0.813 to 0.983, and 0.912 ± 0.036,
95% CI: 0.842 to 0.982, respectively. There was no signifi-
cant difference in discriminating power between HDL and
APO A-I (P = 0.587). When those patients with OF weres stratified by persistent organ failure
nt) Organ failure (persistent) P-value
(n = 35)
54 (44 to 71) 0.159
24/11 0.173
25.3 ± 3.6 0.300
69.3 ± 12.3 0.415
17/15/1/2 0.126
13.20 ± 7.3 0.888
10.30 ± 2.2 0.718
112 (49 to 229) 0.178
26.5 (14 to 50.5) 0.011
2.6 (1.1 to 3.8) 0.003
2.6 (1.2 to 8.0) 0.081
1.3 (1.2 to 1.6) 0.044
6 (5 to 7) 0.009
22 (15 to 28) <0.001
8 (6 to 12.3) <0.001
6.5 (4.8 to 10) <0.001





94 (83 to 135) 0.017
153 (103 to 290) 0.868
8 (5 to 15) <0.001
42 (30 to 77) 0.029
48 (31 to 54) <0.001
211 (104 to 552) 0.005
12 (6.1 to 25) 0.048




11 (5.8 to 17.3) 0.009
le; F female; BMI body mass index; ERCP endoscopic retrograde
tio; APACHE acute physiology and chronic health evaluation; SOFA sequential
; APO A-I apolipoprotein A-I; TNF tumor necrosis factor; CRP C-reactive protein.
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persistent OF was 0.895 ± 0.045 (mean ± SEM), 95% CI
0.808 to 0.983, and 0.904 ± 0.037, 95% CI 0.832 to 0.976
respectively (P = 0.838). These results indicate that both
HDL and APO A-I are good markers in this clinical set-
ting. Meanwhile, we also evaluated the discriminating abil-
ity of CRP because it has been used as a biomarker to
predict severity [1]. The area under ROC curve for CRP
obtained by analyzing all patients or patients with OF was
0.603 ± 0.061, and 0.568 ± 0.076, respectively. Pair-wise
comparisons of AUROC showed that both HDL and APO
A-I gave significantly higher AUROC and thus, better
predictive accuracy than CRP when analyzing all patients
(P <0.001 relative to both HDL and APO A-I) or patients
with OF (P <0.001 relative to both HDL and APO A-I).
The best cutoff points of HDL and APO A-I to predict
persistent OF remained the same when analyzing all pa-
tients or patients with OF. Table 5 shows the predictive
values of the chosen cutoff points (16.5 mg/dl for HDL,
64 mg/dl for APO A-I), which gave the best Youden index,
for prediction of persistent OF.
We also evaluated the performance of different scores.
We found that there is no difference in discriminating
power of predicting persistent OF among HDL, APO A-I
and different scores (Additional file 1: Table S1).
Discussion
The major findings of this study are as follows: (1) low
levels of APO A-I and HDL are associated with high
levels of inflammatory cytokines, persistent OF, infected
necrosis and hospital mortality in patients with predicted
SAP admitted to ICU; (2) APO A-I and HDL can serve
as biomarkers to differentiate persistent OF from transi-
ent OF in this clinical setting.
In acute patients with pancreatitis, inflammatory reac-
tion initially takes place within the pancreas. Subse-
quently, inflammatory cytokines induce hepatic synthesis
of acute-phase proteins and mediate distant organ failure
in the setting of SAP [25]. Despite improvements in crit-
ical care, the mortality rate of SAP remains high and is
closely associated with the development of persistent OFTable 5 HDL and APO A-I for prediction of persistent
organ failure
Sensitivity Specificity PPV NPV Accuracy
All patients
HDL <16.5 mg/dl 0.886 0.839 0.861 0.867 0.864
APO A-I <64 mg/dl 0.943 0.806 0.846 0.926 0.879
Patients with organ failure
HDL <16.5 mg/dl 0.886 0.850 0.912 0.810 0.873
APO A-I <64 mg/dl 0.943 0.850 0.917 0.895 0.909
HDL, high-density lipoprotein; APO A-I, apolipoprotein A-I; PPV, positive
predictive value; NPV, negative predictive value.and subsequent sepsis [26]. Gut barrier failure with en-
suing endotoxin translocation has been proposed as a
major contributor to the development of OF in SAP
[26]. Increased intestinal permeability occurs early after
onset of acute pancreatitis and closely correlates with
disease severity, levels of endotoxemia, and release of in-
flammatory cytokines, which initiate and propagate the
deleterious consequences of severe inflammation, such
as organ failure and mortality [26,27]. Recently, the cap-
ability of lipoprotein to bind and neutralize endotoxin has
drawn more and more attention. When endotoxin was
added to normal human whole blood in vitro, the binding
of endotoxin to lipoproteins displays high specificity, with
HDL binding the majority of endotoxin (60%) [28]. In this
regard, serum lipoprotein may represent an integral part
of innate immunity against organ injury in SAP.
In addition to the ability to neutralize endotoxin, HDL
has also been shown to have antioxidant and anti-
inflammatory properties [29]. In this regard, free radicals
and oxidative stress have been implicated in the patho-
genesis of acute pancreatitis and have been shown to
correlate with the severity of pancreatitis [30,31]. Con-
sistent with previous reports on critically ill patients
[32-34], we showed that the levels of HDL and APO A-I
at admission to ICU were significantly lower in non-
survivors. We also demonstrated that the levels HDL
and APO A-I were significantly lower in patients with
persistent OF, while the levels of TNF-α, and IL-6 were
lower in those with transient OF. Although hypolipide-
mia is a well-recognized phenomenon in critical illness
[32,33], the mechanisms are incompletely understood
and probably multi-factorial. Both decreased synthesis
and enhanced catabolism may be involved. It has been
shown that TNF-α and IL-6 can dose-dependently in-
hibit synthesis of apolipoprotein in hepatic cell lines
[15]. On the other hand, over-expression of secretory
phospholipase A2, an acute-phase protein, can induce
rapid catabolism of HDL and APO A-I [35]. Taken to-
gether, high levels of inflammatory cytokines in patients
with SAP may not only impair the biosynthesis of APO
A-I and HDL but also facilitate the degradation of lipo-
protein, rendering these patients even more susceptible
to harmful consequences of inflammation. Additionally,
increased levels of endotoxin in SAP may overwhelm the
already impaired neutralization ability provided by low
levels of HDL and APO A-I and subsequently become
even more unopposed, thus perpetuating the overpro-
duction of inflammatory cytokines. A vicious cycle en-
sues and leads to further failure of multiple organ
functions. Agreeing with this hypothesis, we showed that
serum levels of APO A-I were inversely correlated with
systemic inflammatory states, which was indicated by
serum levels of TNF-α and IL-6 (Table 2). We also dem-
onstrated that the concentrations of APO A-I and HDL
Peng et al. Critical Care  (2015) 19:88 Page 8 of 9decreased progressively as the number of organ failures
increased (Figure 1).
Another novel finding of our study is that APO A-I
and HDL can differentiate persistent OF from transient
OF. In this regard, the existing scoring systems have
shown moderate accuracy in predicting persistent OF
[36]. However, these scoring systems are cumbersome to
use and appeared to have reached their maximal efficacy
in this clinical setting. To improve the capability of pre-
dicting persistent OF, clinicians need to develop new ap-
proaches. In addition to recognized scoring systems,
recent attention has also focused on simple biomarkers
that could give predictive information [37,38], such as
blood urea nitrogen (BUN) and creatinine. Despite these
encouraging results, there are drawbacks in currently
available data that these markers are not necessarily
patho-physiologically linked to the development of the
OF and therefore, elevation of these markers simply re-
flects ongoing OF. Theoretically, patho-physiologically
relevant biomarkers may perform better in this clinical
setting. In this regard, blood lipoprotein may provide im-
portant prognostic information and help risk stratification.
There are limitations of our study. First of all, we stud-
ied these markers in patients admitted to ICU, therefore,
our results may not be generalizable in those patients
with less severe illness. Second, the number of patients
studied was small. Further studies with larger cohorts
are needed to validate our results.
Conclusions
The concentrations of HDL and APO A-I are inversely
related to disease severity in patients with predicted SAP
admitted to ICU. Serum levels of HDL and APO A-I at
admission to ICU can predict persistent OF in this clin-
ical setting. Whether lipid-based treatment can play a
therapeutic role in the management of SAP deserves fur-
ther investigation.
Key messages
 Low levels of APO A-I and HDL are associated with
high levels of inflammatory cytokines, persistent OF,
infected necrosis and hospital mortality in patients
with predicted SAP admitted to ICU
 APO A-I and HDL can serve as biomarkers to
differentiate persistent OF from transient OF in this
clinical setting
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